EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CDK4/6 Inhibition and Stereotactic Radiotherapy in Oligometastatic HR+/HER2− Breast Cancer: Evidence of Immunogenic Modulation and Pseudoprogression

Andrea Emanuele Guerini, Sara Pedretti, Althea Carlino, Marta Maddalo, Eneida Mataj, Ludovica Pegurri, Gianluca Cossali, Paolo Borghetti, Giorgio Facheris, Luca Nicosia, Chiara Valietti, Marco Lorenzo Bonù und 2 weitere

Immuno · 08.06.2026 · 6 (2) · 40

DOI: 10.3390/immuno6020040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immuno, online erschienen am 08.06.2026. Verfasst von Andrea Emanuele Guerini und 13 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A combination of cyclin-dependent kinase 4/6 inhibitors (CDKi) and radiotherapy (RT) may enhance antitumoral immunity, yet clinical evidence of this interaction in HR+/HER2− metastatic breast cancer (MBC) remains limited. This study evaluates the impact of combined CDKi and stereotactic body radiotherapy (SBRT) on immune biomarkers and treatment response.

Methods

We report a case of a 51-year-old woman with oligometastatic HR+/HER2− MBC involving the sacrum. Clinical management included letrozole plus palbociclib and SBRT (30 Gy in 3 fractions). Serial Neutrophil-to-lymphocyte ratio (NLR) measurements, MRI, and PET-CT scans were used to monitor systemic immune modulation and treatment efficacy over a five-year period.

Results

Baseline NLR was 1.068. Following four weeks of CDKi, NLR decreased by 44.7% (0.591). Post-SBRT, a further 17.8% reduction was observed (nadir 0.486). Five months post-RT, MRI showed a volumetric increase in sacral lesions despite clinical improvement. Subsequent PET-CT demonstrated a complete metabolic response, confirming the MRI findings as pseudoprogression. As of January 2026, the patient remains in sustained complete metabolic remission.

Conclusion

The integration of CDKi and SBRT might induce an immune-mediated antitumoral response, evidenced by dynamic NLR reductions and radiologic pseudoprogression. Multimodal imaging is essential to differentiate immune-mediated swelling from true progression in this setting.

Zitieren

APA

Guerini, A. E., Pedretti, S., Carlino, A., Maddalo, M., Mataj, E., Pegurri, L., Cossali, G., Borghetti, P., Facheris, G., Nicosia, L., Valietti, C., Bonù, M. L., Triggiani, L., & Bastia, M. B. D. M. E. (2026). CDK4/6 Inhibition and Stereotactic Radiotherapy in Oligometastatic HR+/HER2− Breast Cancer: Evidence of Immunogenic Modulation and Pseudoprogression. Immuno, 6(2), 40. https://doi.org/10.3390/immuno6020040

Vancouver

Guerini AE, Pedretti S, Carlino A, Maddalo M, Mataj E, Pegurri L, et al. CDK4/6 Inhibition and Stereotactic Radiotherapy in Oligometastatic HR+/HER2− Breast Cancer: Evidence of Immunogenic Modulation and Pseudoprogression. Immuno. 2026;6(2):40. doi:10.3390/immuno6020040

BibTeX
@article{Guerini2026,
  author = {Guerini, Andrea Emanuele and Pedretti, Sara and Carlino, Althea and Maddalo, Marta and Mataj, Eneida and Pegurri, Ludovica and Cossali, Gianluca and Borghetti, Paolo and Facheris, Giorgio and Nicosia, Luca and Valietti, Chiara and Bonù, Marco Lorenzo and Triggiani, Luca and Bastia, Michela Buglione di Monale e},
  title = {CDK4/6 Inhibition and Stereotactic Radiotherapy in Oligometastatic HR+/HER2− Breast Cancer: Evidence of Immunogenic Modulation and Pseudoprogression},
  journal = {Immuno},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {40},
  doi = {10.3390/immuno6020040}
}
Kostenlos starten →